Iatrogenic risk factors and correction of dyslipidemia after liver transplantation

Cover Page

Cite item

Full Text

Abstract

The article analyzes information of the prevalence, causes and mechanisms of development of dyslipidemia in patients after liver transplantation. The authors integrate data from domestic and foreign literature about priorities of choice of lipid-lowering drugs and possible changes in patterns of immunosuppressive drug therapy to reduce the risk of onset and progression of cardiovascular disease in patients who were underwent orthotopic liver transplantation.

About the authors

E. D Kosmacheva

Kuban State Medical University, Ministry of Health of the Russian Federation; The Research Institute-Regional Clinical Hospital №1 named after Prof. S.V.Ochapovsky of the Ministry of Health of the Krasnodar Region

д-р мед. наук, проф., зав. каф. терапии №1 фак-та повышения квалификации и профессиональной переподготовки специалистов ГБОУ ВПО КубГМУ, зам. глав. врача по мед. части ГБУЗ НИИ-ККБ №1 им. проф. С.В.Очаповского, глав. кардиолог Южного федерального округа и Краснодарского края 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4

A. E Babich

The Research Institute-Regional Clinical Hospital №1 named after Prof. S.V.Ochapovsky of the Ministry of Health of the Krasnodar Region

Email: Anna-babich1@yandex.ru
врач-терапевт хирургического отд-ния №1 ГБУЗ НИИ-ККБ №1 им. проф. С.В.Очаповского 350029, Russian Federation, Krasnodar, ul. 1 Maia, d. 16

References

  1. Национальные рекомендации по кардиоваскулярной профилактике. 1-е изд. 2011. Кардиоваск. терапия и профилактика. 2011; 10 (6; Прил. 2).
  2. Gisbert C, Prieto M, Berenguer M et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 1997; 3 (4): 416-22.
  3. Bianchi G, Marchesini G, Marzocchi R et al. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14 (11): 1648-54.
  4. Guckelberger O, Bechstein W.O, Neuhaus R et al. Cardiovascular risk factors in long - term follow - up after orthotopic liver transplantation. Clin Transpl 1997; 11 (1): 60-5.
  5. Laryea M, Watt K.D, Molinari M et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13 (8): 1109-14.
  6. Muñoz L.E, Nañez H, Rositas F et al. Long - term complications and survival of patients after orthotopic liver transplantation. Transplant Proc 2010; 42 (6): 2381-2.
  7. Muñoz S.J, El Genaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 2005; 11 (Suppl. 2): S52-S56.
  8. Kobashigawa J.A, Kasiske B.L. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331-8.
  9. Imagawa D.K, Dawson S, 3rd, Holt C.D et al. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxyl - methylglutaryl - coenzyme A reductase inhibitor pravastatin. Transplantation 1996; 62: 934-42.
  10. Munoz S.J, Deems R.O, Moritz M.J et al. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc 1991; 23: 1480-3.
  11. Lucey M.R, Terrault N, Ojo L et al. Long Term Management of the Successful Adult Liver Transplant: 2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3-26.
  12. Bianchi G, Marchesini G, Marzocchi R et al. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14 (11): 1648-54.
  13. Neal D.A, Tom B.D, Luan J. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 2004; 77 (1): 93-9.
  14. Johnston S.D, Morris J.K, Cramb R et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73 (6): 901-6.
  15. Ciccarelli O, Kaczmarek B, Roggen F. Long - term medical complications and quality of life in adult recipients surviving 10 years or more after liver transplantation. Acta Gastroenterol Belg 2005; 68 (3): 323-30.
  16. Watt K.D, Pedersen R.A, Kremers W.K et al. Evolution of causes and risk factors for mortality post - liver transplant: results of the NIDDK long - term follow - up study. Am J Transpl 2010; 10 (6): 1420-7.
  17. Neal D.A, Gimson A.E, Gibbs P, Alexander G.J. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001; 7 (6): 533-9.
  18. Clark W. Tacrolimus: immunosuppression following liver and kidney transplant. J Clin Pharm Ther 1996; 21: 135-41.
  19. Guckelberger O, Bechstein W.O, Neuhaus R et al. Cardiovascular risk factors in long - term follow - up after orthotopic liver transplantation. Clin Transplant 1997; 11: 60-5.
  20. Rabkin J.M, Corless C.L, Rosen H.R, Olyaei A.J. Immunosuppression impact on long - term cardiovascular complications after liver transplantation. Am J Surg 2002; 183: 595-9.
  21. Stegall M.D, Wachs M.E, Everson G et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64: 1755-60.
  22. Manzarbeitia C, Reich D.J, Rothstein K.D et al. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transpl 2001; 7: 93-9.
  23. Morard I, Dumortier J, Spahr L. Conversion to sirolimus - based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007; 13 (5): 658-64.
  24. Stegall M.D, Everson G.T, Schroter G et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 1997; 25: 173-7.
  25. Boillot O, Mayer D.A, Boudjema K et al. Corticosteroid - free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005; 11: 61-7.
  26. Segev D.L, Sozio S.M, Shin E.J et al. Steroid avoidance in liver transplantation: meta - analysis and meta - regression of randomized trials. Liver Transpl 2008; 14: 512-25.
  27. Moench C, Barreiros A.P, Schuchmann M et al. Tacrolimus monotherapy without steroids after liver transplantation - a prospective randomized double - blinded placebo - controlled trial. Am J Transpl 2007; 7: 1616-23.
  28. Siddharth Singh, Watt K.D. Long - term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc 2012; 87 (8): 779-90.
  29. Космачева Е.Д., Бабич А.Э. Особенности ведения пациентов с артериальной гипертензией после трансплантации печени. Системные гипертензии. 2014; 4: 55-7.
  30. Pokrovskii V.M, Kompaniets O.G. Influence of the level of blood pressure on the regulatory - adaptive state. Hum Physiol 2012; 38 (5): 539-42.
  31. Покровский В.М., Компаниец О.Г. Регуляторно - адаптивный статус пациентов с гипертонической болезнью при медикаментозном достижении целевых уровней артериального давления. Системные гипертензии. 2011; 2: 58-60.
  32. Ратова Л.Г., Чазова И.Е. Эффективность и безопасность лечения β - адреноблокатором III поколения пациентов с артериальной гипертонией. Consilium Medicum. 2009; 5.
  33. Компаниец О.Г., Аверин Е.Е. Приоритеты выбора диуретиков при лечении гипертонической болезни: доказательная медицина, рекомендательные документы и реальная клиническая практика. Системные гипертензии. 2013; 1: 62-5.
  34. Карташева Е.Д., Линчак Р.М. Роль β - адреноблокаторов в лечении и профилактике сердечно - сосудистых заболеваний: акцент на карведилол. Трудный пациент. 2010; 8 (5): 21-7.
  35. Пономарева А.И., Одноволов О.Т., Компаниец О.Г., Чернявская Д.Е. Комбинированная фармакотерапия артериальной гипертензии. Consilium Medicum. 2013; 1: 11-4.
  36. International Atherosclerosis Society, IAS. Меморандум Международного общества по изучению атеросклероза: Общие рекомендации по лечению дислипидемии. 2014; с. 1-67. http://scardio.ru/content/Guidelines/IAS/PositionPaperRussianlanguage.pdf США / International Atherosclerosis Society, IAS. Memorandum Mezhdunarodnogo obshchestva po izucheniiu ateroskleroza: Obshchie rekomendatsii po lecheniiu dislipidemii. 2014; s. 1-67. http://scardio.ru/content/Guidelines/IAS/PositionPaper-Russianlanguage.pdf SShA [in Russian]
  37. Martin J.E, Cavanaugh T.M, Trumbull L. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transpl 2008; 22 (1): 113-9.
  38. Asberg A. Interactions between cyclosporin and lipid - lowering drugs: implications for organ transplant recipients. Drugs 2003; 63 (4): 367-78.
  39. Общероссийская общественная организация трансплантологов «Российское трансплантологическое общество». Трансплантация печени. Национальные клинические рекомендации 2013. http://transpl.ru/images/cms/data/pdf/nacional_nye_klinicheskie_rekomendacii_po_transplantacii_pecheni.pdf
  40. Государственный реестр лекарственных средств. http://grls.rosminzdrav.ru
  41. Mc Kenney J.M, Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm 2007; 64 (6): 595-605.
  42. Lee S, Gura K.M, Puder M. Omega-3 fatty acids and liver disease. Hepatology 2007; 45 (4): 841-5.
  43. Almutairi F, Peterson T.C, Molinari M. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl 2009; 15 (5): 504-8.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies